Lupus Research Alliance News

New York, NY– June 27, 2019.  The Lupus Research Alliance (LRA) and its affiliate, Lupus Therapeutics, announced that it has broadened its collaboration with Bristol-Myers Squibb (BMS) to assess the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN). This expands the existing collaboration in systemic lupus erythematosus (SLE). Lupus nephritis refers […] READ MORE

June 25, 2019 Caroline Donovan, Manager of Patient Engagement at Lupus Research Alliance (LRA) affiliate Lupus Therapeutics (LT) took part in a panel discussion at the DIA 2019 (Drug Information Association) annual meeting, aimed at finding ways to make sure that diverse groups of patients can make informed choices about joining a clinical trial. Ms. […] READ MORE

June 24, 2019 Patients with cutaneous lupus develop rashes because immune cells move into the skin and cause inflammation. With a Target Identification in Lupus (TIL) grant from the Lupus Research Alliance, Dr. Jillian Richmond of the University of Massachusetts Medical School and colleagues found what lures the immune cells into the skin of people […] READ MORE

June 20, 2019 The investigational drug 2DG, tested as a cancer treatment, shows promise for lupus in new results reported by researchers from Japan at the European League Against Rheumatism (EULAR) 2019 annual meeting. Previous research had shown that the a potential drug, 2DG, increases the numbers of regulatory T cells, which turn down the […] READ MORE

June 20, 2019 As reported by the National Institutes of Health (NIH), research published by the NIH Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) “provides new insights into tissue damage for these autoimmune conditions.” AMP RA/SLE is a public-private partnership between the NIH, the pharmaceutical industry and non-profit organizations, including the Lupus […] READ MORE

NEW YORK, NY. June 19, 2019. The U.S. House of Representatives today passed the Fiscal Year 2020 Defense Appropriations Act, which allocates the Lupus Research Alliance advocate’s full request for $10 million — double the current budget — for the Lupus Research Program in the Department of Defense’s (DoD) Congressionally Directed Medical Research Program. The […] READ MORE

June 19,2019 Partly funded by the Lupus Research Alliance, new results presented at the European Congress of Rheumatology (EULAR) 2019 suggest that some potential cancer treatments may also help patients with lupus.  Dr. Amr Sawalha of the University of Pittsburgh and colleagues have discovered a similarity between immune cells in lupus and some kinds of […] READ MORE

June 20, 2019 Michael Lauria knows only too well that lupus is not just a woman’s disease – he was diagnosed in the prime of his life – when he was just 32 years old. And he is counting on the Lupus Research Alliance to find the answers that will change his life. Young, fit, […] READ MORE

Boston, MA. June 19, 2019. The Lupus Research Alliance has awarded its 2019 Lupus Insight Prize to Ignacio Sanz, MD, for discovering that certain little-understood immune system cells are a major source of the harmful proteins that promote lupus symptoms. His work could spark new treatments for the disease and help doctors determine which patients […] READ MORE

June 12, 2019 A study presented at EULAR showed that ongoing maintenance therapy with the immunosuppressive drug cyclosporine helped lower proteinuria — the level of protein in urine — faster than other immunosuppressive drugs mycophenolate mofetil or azathioprine in people with lupus nephritis.  The three were comparable in their ability to cause remission of Lupus […] READ MORE

June 18, 2019 A common type of bacteria living in the gut may spark a common lupus complication called antiphospholipid syndrome, a study partly funded by the Lupus Research Alliance shows. Antiphospholipid syndrome can lead to blood clots and miscarriages.  Led by Dr. Martin Alexander Kriegel of Yale School of Medicine, the research may also […] READ MORE

Kezar Life Sciences announced positive results from the MISSION Phase 1 study testing the investigational KZR-616 as a treatment for lupus.  The presentation was at the European League Against Rheumatism (EULAR) 2019 annual meeting. The primary goal of the study was to assess if KZR-616 is safe and well tolerated. The study also looked at […] READ MORE